	Application No.	Applicant(s)
Notice of Allowability	10/521,022	KANG ET AL.
	Examiner	Art Unit
	Ganapathy Krishnan	1623
	, Ganapaniy Krisinian	1023
The MAILING DATE of this communication appearance All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIOF of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this ap or other appropriate communication IGHTS. This application is subject t	pplication. If not included n will be mailed in due course. <b>THIS</b>
1. This communication is responsive to <u>August 2, 2007</u> .	•	1
2. The allowed claim(s) is/are <u>1-4</u> .	•	
3.   Acknowledgment is made of a claim for foreign priority ur  a)   All b)   Some⁺ c)   None of the:		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
		•
Attachment(s)		
1. Notice of References Cited (PTO-892)	5. Notice of Informal F	Patent Application
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. Interview Summary	
3. ⊠ Information Disclosure Statements (PTO/SB/08),	Paper No./Mail Da 7. 🛛 Examiner's Amendr	
Paper No./Mail Date <u>03/06</u> ; <u>05/06</u> 4.  Examiner's Comment Regarding Requirement for Deposit	8. 🖾 Examiner's Stateme	ent of Reasons for Allowance
of Biological Material		
	9. 🗌 Other	2CD 813/07
	SHAOJIA AN SUPERVISORY	INA JIANG, PH.D. PATENT EXAMINER

## REASONS FOR ALLOWANCE

The closest prior art, Xu et al (Document #AM in the IDS of March 31, 2006) teaches the preparation of 2-deoxy-L-ribose from D-ribose via the ring opening of 5-trityl protected D-ribose with sodium borohydride reduction to give the open chain structure 4. Structure 4 is then converted to L-ribose using a series of steps involving deprotection of the trityl group and oxidation of the 5-OH group followed by base catalyzed ring closure (Scheme 1). The L-ribose so obtained is finally converted to the deoxy sugar by a reductive rearrangement (Scheme 3). The process as instantly claimed obtains 2-deoxy-L-ribose starting from protected 2-deoxy-D-ribose via the inversion of the stereochemistry of the hydroxyls at the 3- and 4- positions using the metal salt of an organic acid for the said inversion. This step of inversion using a metal salt of an organic acid is seen as the novelty and is not taught or suggested by the prior art of record.

## **EXAMINER'S AMENDMENT**

The attached Abstract typed on a separate sheet replaces the first page of the WIPO document filed 1/12/2005.

Any comments considered necessary by the applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance".

Any inquiry concerning this communication should be directed to Shaojia A. Jiang, Supervisory Patent Examiner of Art Unit 1623 at 571-272-0627.